Synchronously accelerating neglected disease research the Astellas way
This article was originally published in Scrip
Astellas is tapping into the rarefied world of high physics to advance its nascent research programme on neglected tropical diseases, unveiling an expanded collaboration with Japan's High Energy Accelerator Research Organisation (KEK).
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.